COVID-19: Developing a large-scale synthesis of a drug potentially curing COVID-19 for the Canadian manufacturing industry

COVID-19：为加拿大制造业开发一种可能治愈 COVID-19 的药物的大规模合成

• 批准号: 549986-2020
• 负责人: Dudding, Travis
• 金额: $ 3.64万
• 依托单位: Brock University
• 依托单位国家: 加拿大
• 项目类别: Alliance Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=701312
• 关键词: COVID; 19; Developing; large; scale

The recent outbreak of coronavirus infectious disease 2019 (COVID-19) has gripped the world with apprehension and evoked a scare of epic proportion as this global pandemic continues to causes deaths with nearly two million confirmed cases and over 120,000 confirmed deaths worldwide as of April 14, 2020. With this untold millions of people's lives are being affected as a result of mandatory isolations/quarantines and worldwide health systems are being overwhelmed and the global economy damaged as a ripple effect of the COVID-19 outbreak. Repurposing of hydroxychloroquine, a widely used anti-malarial and autoimmune disease drug, was recently identified as a potential broad-spectrum antiviral drug, with promise in treating COVID-19. Importantly, hydroxychloroquine is a proven safe drug used for more than 70 years and, thus, streamlining it clinical use against COVID-19. While the therapeutic potential of hydroxychloroquine is promising, the existing supply chain of this drug in Canada is limited; thus, presenting a real supply and demand bottleneck. This is especially pertinent given mounting border closures that inevitably will lead to increasing cost of offshore drug imports. The proposed partnership with Biolyse Pharma Cooperation involves the development of a reliable Kilogram-scale synthesis of hydroxychloroquine, a potential broad-spectrum antiviral drug, with promise in treating COVID-19. In doing so, the company partner will position themselves at a strategic place for offering a low-cost, readily available drug for saving (Canadian) lives from COVID-19, while benefiting economically and fostering Canadian based Pharma production. At the same time, most importantly this undertaking will provide Canada with a resource to treat COVID-19 infected patients.

最近爆发的2019冠状病毒感染性疾病（COVID-19）令全球忧心忡忡，并引发了前所未有的恐慌，因为截至2020年4月14日，这场全球大流行病继续导致全球近200万例确诊病例和超过120，000例确诊死亡。在此情况下，数百万人的生活因强制隔离/隔离而受到影响，全球卫生系统不堪重负，全球经济因COVID-19爆发的涟漪反应而受损。 羟氯喹是一种广泛使用的抗疟疾和自身免疫性疾病药物，最近被确定为一种潜在的广谱抗病毒药物，有望治疗COVID-19。重要的是，羟氯喹是一种已被证明安全的药物，使用了70多年，因此，它简化了抗COVID-19的临床使用。虽然羟氯喹的治疗潜力很有希望，但加拿大这种药物的现有供应链有限;因此，出现了真实的供需瓶颈。这一点尤其重要，因为边境关闭越来越多，不可避免地会导致境外毒品进口成本增加。 与Biolyse Pharma Cooperation的拟议合作关系涉及开发一种可靠的公斤级羟氯喹合成方法，羟氯喹是一种潜在的广谱抗病毒药物，有望治疗COVID-19。在这样做的过程中，公司合作伙伴将自己定位在一个战略位置，提供低成本，现成的药物，以挽救（加拿大）的生命从COVID-19，同时受益于经济和促进加拿大的制药生产。 同时，最重要的是，这项承诺将为加拿大提供治疗COVID-19感染患者的资源。